| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/28/2006 | WO2006100489A2 A transdermal topical composition and its uses |
| 09/28/2006 | WO2006100485A1 A topical composition and its uses |
| 09/28/2006 | WO2006099779A1 A rgd-containing cyclic peptid and the active-targeting liposome thereof |
| 09/28/2006 | WO2006083761A3 Solvent/polymer solutions as suspension vehicles |
| 09/28/2006 | WO2006047476A3 Therapeutic and delivery methods of prostaglandin ep4 agonists |
| 09/28/2006 | WO2006034488A3 Cysteine engineered antibodies and conjugates |
| 09/28/2006 | WO2005094422A3 Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases |
| 09/28/2006 | WO2005094234A3 Dietary supplement for treating digestive system disorders |
| 09/28/2006 | WO2005074650A3 Modified human four helical bundle polypeptides and their uses |
| 09/28/2006 | WO2005065718A8 Antitumour treatments with metxia-p450 and cyclophosphamide or 5t4 vaccine |
| 09/28/2006 | WO2005054303A8 Cyclodextrin dimers and derivatives thereof, methods for preparing them and their use, in particular, for solubilizing pharmacologically active substances |
| 09/28/2006 | US20060217397 Sustained release ranolazine formulations |
| 09/28/2006 | US20060217341 DNA vaccine formulations |
| 09/28/2006 | US20060217337 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| 09/28/2006 | US20060217336 Synthesizing a double stranded nucleic acid molecule used for treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 09/28/2006 | US20060217335 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| 09/28/2006 | US20060217334 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| 09/28/2006 | US20060217321 Compositions to improve tic disorders |
| 09/28/2006 | US20060217320 Soft gel formulations for saquinavir |
| 09/28/2006 | US20060217317 Proteases of human kallikrein 2 (hK2); tissue imaging |
| 09/28/2006 | US20060217313 5-CNAC as oral delivery agent for parathyroid hormone fragments |
| 09/28/2006 | US20060217309 Novel cyclosporine analog formulations |
| 09/28/2006 | US20060217304 Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders |
| 09/28/2006 | US20060217293 Coupling low-molecular substances to a modified polysaccharide |
| 09/28/2006 | US20060216782 Methods for expression and purification of immunotoxins |
| 09/28/2006 | US20060216772 Interfacial biomaterials for binding metal substrates |
| 09/28/2006 | US20060216758 Antibodies to transferrin receptor-like proteins |
| 09/28/2006 | US20060216351 Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers |
| 09/28/2006 | US20060216349 Ibuprofen composition |
| 09/28/2006 | US20060216342 Micelle delivery system loaded with a pharmaceutical agent |
| 09/28/2006 | US20060216330 Peptides having an ace inhibiting effect |
| 09/28/2006 | US20060216328 Topical composition comprising a cyclofructan, a carrier and a drug |
| 09/28/2006 | US20060216302 Immunological markers |
| 09/28/2006 | US20060216285 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| 09/28/2006 | US20060216283 Inhibition of secretion from non-neuronal cells |
| 09/28/2006 | US20060216268 Denaturants for sympathomimetic amine salts |
| 09/28/2006 | US20060216265 Dendrimers as molecular translocators |
| 09/28/2006 | US20060216261 Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same |
| 09/28/2006 | US20060216244 Delivery of compounds for the treatment of parkinson's through an inhalation route |
| 09/28/2006 | US20060216243 Delivery of Beta-Blockers Through An Inhalation Route |
| 09/28/2006 | US20060216231 Methods for diagnosing and treating tumors and suppressing cd promoters |
| 09/28/2006 | US20060214037 Wet milling process |
| 09/28/2006 | CA2602946A1 Delivery systems and methods for diagnosing and treating cardiovascular diseases |
| 09/28/2006 | CA2602018A1 A transdermal topical composition and its uses |
| 09/28/2006 | CA2602017A1 A topical composition and its uses |
| 09/28/2006 | CA2601373A1 Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
| 09/28/2006 | CA2601363A1 Nanoparticulate biphosphonate compositions |
| 09/28/2006 | CA2601315A1 Fucoidan compositions and methods for dietary and nutritional supplements |
| 09/28/2006 | CA2600533A1 Pharmaceutical composition |
| 09/28/2006 | CA2599018A1 Methods and systems for operating an aerosol generator |
| 09/27/2006 | EP1705190A2 Peptide derivatives |
| 09/27/2006 | EP1704878A2 Crosslinked polymer compositions and methods for their use |
| 09/27/2006 | EP1704870A1 Use of iron compounds as radiosensitizers |
| 09/27/2006 | EP1704865A2 Treatment of C. difficile toxin B associated conditions |
| 09/27/2006 | EP1704864A2 Process for producing an injectable pharmaceutical preparation |
| 09/27/2006 | EP1704858A1 Propofol-containing fat emulsion preparation |
| 09/27/2006 | EP1704160A2 Methods and compositions for identifying rna-binding proteins |
| 09/27/2006 | EP1703904A2 Taxoid-fatty acid conjugates and pharmaceutical compositions thereof |
| 09/27/2006 | EP1703899A2 Stabilised compositions of factor vii polypeptides |
| 09/27/2006 | EP1703896A2 Pharmaceutical compositions comprising midazolam in a high concentration |
| 09/27/2006 | EP1703895A2 Controlled release cgrp delivery composition for cardiovascular and renal indications |
| 09/27/2006 | EP1703892A2 Uv light-stable semi-solid transdermal systems comprising a photosensitive active agent and an uv-absorbing component |
| 09/27/2006 | EP1481017B8 Biodegradable polymeric material for biomedical applications |
| 09/27/2006 | EP1471890B1 Pharmaceutical dosage form for mucosal delivery |
| 09/27/2006 | EP1368008B1 Transdermal therapeutic system for the administration of the partial dopamine-d2 agonist aripiprazol |
| 09/27/2006 | EP1322293B1 Modified release formulation |
| 09/27/2006 | EP1251832B1 Shell-and-core dosage form approaching zero-order drug release |
| 09/27/2006 | EP1246622B1 Novel substituted benzimidazole dosage forms and method of using same |
| 09/27/2006 | EP1173222B1 Conjugate having a cleavable linkage for use in a liposome |
| 09/27/2006 | EP1140196B1 pharmaceutical solutions comprising triphenylethylene antiestrogens |
| 09/27/2006 | EP1131053B1 Nanocapsules and method of production thereof |
| 09/27/2006 | EP1123088B1 Sustained-release pharmaceutical formulations containing a cgmp pde-5 inhibitor |
| 09/27/2006 | EP1000079B1 New formulation |
| 09/27/2006 | EP0889733B1 Stabilised growth hormone formulation and method of preparation thereof |
| 09/27/2006 | CN1838969A Preparation for percutaneous/permucosal absorption |
| 09/27/2006 | CN1838964A Treatment and prevention of pulmonary conditions |
| 09/27/2006 | CN1836731A Saccharide combination possessing protective function for life active compound |
| 09/27/2006 | CN1836730A Intensified additive for chondroitin sulfate capsule formulation and tablet and its preparation method |
| 09/27/2006 | CN1836714A Soft capsule for treating prostate disease and its preparation method and quality control method |
| 09/27/2006 | CN1836676A Method for preparing and controlling the quality of lucid ganoderma spore powder soft capsule |
| 09/27/2006 | CN1836654A Pharmaceutical composition for stabilizing ambroxol hydrochloride granula |
| 09/27/2006 | CN1836653A Rosiglitazone slow-release tablet and its preparation method |
| 09/27/2006 | CN1836651A Levogyration sulpiride injection and its preparation method |
| 09/27/2006 | CN1276779C Hollow capsule material composition of plant polysaccharide and production method of hollow capsule |
| 09/27/2006 | CN1276750C Diclofenac sodium oral preparation |
| 09/27/2006 | CN1276748C Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 09/26/2006 | US7112654 Ligand for vascular endothelial growth factor receptor |
| 09/26/2006 | US7112568 an anti-allergic agent, comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells |
| 09/26/2006 | US7112567 reactive entity (maleimide) coupled to the peptide conjugated to blood protein such as immunoglobulins, including IgG and IgM, serum albumin, ferritin, steroid binding proteins, transferrin, thyroxin binding protein, alpha -2-macroglobulin, haptoglobin, etc. |
| 09/26/2006 | US7112565 Stabilized pharmaceutical composition in lyophilized form |
| 09/26/2006 | US7112562 Insulin conjugates and methods of use thereof |
| 09/26/2006 | US7112561 Pharmaceutical compositions and methods for insulin treatment |
| 09/26/2006 | US7112436 Conjugate for modifying interactions between proteins |
| 09/26/2006 | US7112340 Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| 09/26/2006 | US7112339 Compositions for controlled release of a biologically active agent, and the preparation thereof |
| 09/26/2006 | US7112338 Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 09/26/2006 | US7112337 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic |
| 09/26/2006 | US7112336 In an insoluble matrix, such as shellac, high molecular weight polyethylene glycol polyvinyl alcohol, lactic acid - glycolic acid copolymer or sugars. Particularly preferred compounds are: enrofloxacin, danofloxacin and sarafloxacin |
| 09/26/2006 | US7112317 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker. |
| 09/26/2006 | CA2305762C Delayed total release gastrointestinal drug delivery system |